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Abstract
Chemotherapy treatment of cancer remains a challenge due to the molecular and functional
heterogeneity displayed by tumours originating from the same cell type. The pronounced
heterogeneity makes it difficult for oncologists to devise an effective therapeutic strategy for
the patient. One approach for increasing treatment efficacy is to test the chemosensitivity of
cancer cells obtained from the patient’s tumour. 3D culture represents a promising method
for modelling patient tumours in vitro. The aim of this study was therefore to evaluate how
closely short-term spheroid cultures of primary colorectal cancer cells resemble the original
tumour. Colorectal cancer cells were isolated from human tumour tissue and cultured as
spheroids. Spheroid cultures were established with a high success rate and remained viable
for at least 10 days. The spheroids exhibited significant growth over a period of 7 days and
no difference in growth rate was observed for spheroids of different sizes. Comparison of
spheroids with the original tumour revealed that spheroid culture generally preserved ade-
nocarcinoma histology and expression patterns of cytokeratin 20 and carcinoembryonic
antigen. Interestingly, spheroids had a tendency to resemble tumour protein expression
more closely after 10 days of culture compared to 3 days. Chemosensitivity screening using
spheroids from five patients demonstrated individual response profiles. This indicates that
the spheroids maintained patient-to-patient differences in sensitivity towards the drugs and
combinations most commonly used for treatment of colorectal cancer. In summary, short-
term spheroid culture of primary colorectal adenocarcinoma cells represents a promising in
vitro model for use in personalized medicine.
Introduction
Cancer remains a major cause of death in developed countries despite significant progress in
understanding the biology of cancer and development of molecular targeted therapies [1–3].
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Tumours originating from the same cell type display molecular and functional heterogeneity,
which represents an obstacle for developing new drugs and predicting likely responders [3,4].
Currently, clinicians rely on histopathological staging of the tumour [5,6] plus a limited num-
ber of molecular tests [7], when devising a therapeutic strategy for each patient. Great effort
has been put into identifying biomarkers that can predict clinical response to specific treat-
ment regimens, but few have demonstrated sufficient precision for use in clinical practice [8].
One major reason for the shortcomings of this approach lies within the complexity of the sig-
nalling networks that drive tumour growth [9]. Functional assessment of the individual
tumour is therefore believed to be of greater clinical value than the molecular footprint.
A promising approach is to test the therapeutic response of cancer cells obtained from the
patient’s own tumour towards a variety of drugs. Viable cancer cells can be isolated from
freshly obtained tumour tissue and subsequently exposed to therapeutic drugs under con-
trolled experimental conditions [10–15]. Methods for propagating primary cancer cells in the
laboratory range from conventional, 2D cell monolayers to more advanced 3D culture systems
[16] as well as engraftment of tumour tissue into immunodeficient rodents as patient-derived
tumour xenografts [17]. Extensive evidence demonstrates that 3D culture of cancer cells mim-
ics in vivo tumour conditions more closely than conventional 2D culture with respect to: 1)
cell morphology and organisation [18,19], 2) cell hierarchy and heterogeneity [20,21], 3) pro-
tein and gene expression patterns [20,22], 4) growth patterns and distribution of proliferating
and apoptotic cells [20,23], 5) cell-cell and cell-matrix interactions [18,19] and 6) metabolic
gradients of for example oxygen and drug penetration [24–26]. Patient-derived tumour xeno-
grafts also recapitulate many features of the original tumour [17], but this technique needs
considerable amounts of tumour tissue, requires several months to evaluate therapeutic re-
sponse and is very costly [27]. 3D culture systems have potential to assess therapeutic response
faster and at a lower cost than PDTX models, while retaining important features and function-
alities of the original tumour.
Colorectal cancer is one of the most frequently diagnosed cancers with more than 1.2 mil-
lion new annual cases worldwide [1]. Despite aggressive multidisciplinary therapy, the overall
5-year survival is only about 60% in the Western World [28,29]. The need for optimization of
chemotherapy is therefore pivotal, and we set out to validate a 3D culture system for in vitro
chemosensitivity testing of primary colorectal cancer cells. Several research groups have previ-
ously demonstrated that fragments of human colorectal tumours form rounded multicellular
structures in 3D culture, termed “spheroids” or “organoids”, and that these structures can be
propagated in vitro [30–33]. Chemosensitivity testing requires a robust method with a high
success rate for isolation of cancer cells from primary tumour tissue. In order to achieve strong
correlation between the test results and the clinical response, the isolated cells should retain
essential characteristics of the original tumour.
The aim of the current study was to evaluate how closely primary colorectal cancer cells
maintained in short-term 3D culture as spheroids resemble the original tumour and whether
the spheroids are suitable for chemosensitivity testing. We established colorectal spheroid cul-
tures from human tumour tissue and characterized the cultures in relation to the original
tumours. The spheroids were exposed to standard colorectal chemotherapeutic regimens and
response profiles were determined for cultures from different patients.
Materials and methods
Patient samples
Tissue samples were collected from 22 patients with colorectal cancer undergoing surgical
resection of their primary tumour at Bispebjerg Hospital and Hvidovre Hospital, Copenhagen,
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Denmark. Furthermore, tissue samples were collected from three patients with metastatic
colorectal cancer undergoing surgical resection of their liver metastases at Rigshospitalet,
Copenhagen, Denmark. Fresh tumour tissue was collected by a pathologist before routine pro-
cessing of the specimen. Collected tumour tissue was placed in cold PBS with antibiotics (500
U/ml penicillin, 500 μg/ml streptomycin, 100 μg/ml gentamicin and 2.5 μg/ml amphotericin
B) and transported to the laboratory on ice. Tumours other than adenocarcinomas were
excluded from the study after receiving the pathology report. The study protocol was approved
by the Regional Committee on Health Research Ethics—Capital Region of Denmark (protocol
no. H-1-2011-125) and written informed consent was obtained from all patients.
Spheroid preparation and culture
Spheroids were prepared using a modified version of the protocol published by Kondo et al.
[31]. Tumour tissue was washed in PBS with antibiotics, visible fatty and necrotic areas were
removed with a scalpel and the tissue was minced into 1–2 mm pieces. Tissue was digested
with 1 mg/ml collagenase type II (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) in
PBS with antibiotics for 20 min at 37˚C. The tissue suspension was filtered sequentially
through the following filters: 230 μm mesh filter (Sigma-Aldrich, St. Louis, MO, USA), 100 μm
cell strainer (BD Biosciences, Franklin Lakes, NJ, USA), 40 μm cell strainer (BD Biosciences,
Franklin Lakes, NJ, USA),) and 30 μm pre-separation filter (MACS, Miltenyi Biotec, Bergisch
Gladbach, Germany). Tissue retained by the 230 μm filter was collected and redigested for 10
min at 37˚C and passed through the filters again. This step was repeated until all tissue passed
through the 230 μm filter. Retained tumour fragments were collected from the 100 μm, 40 μm
and 30 μm filters, separating released fragments into three fractions according to size. The iso-
lated tumour fragments were seeded in stem cell medium (StemPro hESC SFM, Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with antibiotics (200 U/ml penicillin,
200 μg/ml streptomycin, 100 μg/ml gentamicin and 2.5 µg/ml amphotericin B) in petri dishes
coated with agarose (Sigma-Aldrich, St. Louis, MO, USA) and cultured at 37˚C in a 5% CO2
humidified incubator (MCO-19AIC(UV), Panasonic, Ha¨gersten Sweden).
Spheroid forming efficacy and culture success
After 3 days of culture, the isolated tumour fragments were inspected under the microscope
and their spheroid forming efficacy evaluated. For each size fraction, 50 tumour fragments
were examined by light microscopy (Diaphot 200, Nikon, Birkerød, Denmark) at 100x magni-
fication and scored according to whether they had formed spheroids (rounded, smooth surface
without clearly defined individual cells) or not (rippled, rough surface with clearly defined
individual cells). Spheroid forming efficacy across size fractions was compared by one-way
repeated measures ANOVA. Culture success was evaluated by counting the number of formed
spheroids. Tumour fragments were aspirated, washed in PBS and filtered to remove single
cells and debris. The retained spheroids were counted by light microscopy at 40x magnifica-
tion. Spheroid preparations with a total number of 150 spheroids or more were considered
successful.
Spheroid growth
After 3 days of culture, spheroids were washed in PBS, filtered and resuspended in fresh stem
cell medium. Spheroids were mixed 1:1 with Matrigel (BD Biosciences, Franklin Lakes, NJ,
USA) and seeded in 96-well plates coated with agarose at a density of approximately 25 spher-
oids per well. Plates were incubated for 30 min at 4˚C followed by polymerisation of Matrigel
for 30 min at 37˚C. The spheroids were cultured for 7 days at 37˚C in a 5% CO2 humidified
Spheroid culture as an in vitro model for personalizing cancer medicine
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incubator and light microscopy images were obtained with a digital camera (MU300,
AmScope, Irvine, CA, USA) of individual wells every day. Spheroid areas were measured on
the obtained images using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014). Relative changes in spheroid
size during 7 days of culture were assessed by RMANOVA and one-way repeated measures
ANOVA.
Formalin-fixed paraffin-embedded sections of tumour tissue and
spheroids
Resected colorectal tissue was fixed in 4% formalin for a minimum of 48 h and cut into tissue
blocks. Spheroids were fixed in 4% formalin O/N at 4˚C and embedded in 2% agarose. After
dehydration in graded alcohol and xylene, tissue blocks and spheroid-containing agarose
discs were embedded in paraffin. Sections of 2–4 μm were cut using a microtome (HM 450,
Microm, Thermo Fisher Scientific, Waltham, MA, USA) and mounted on FLEX IHC micro-
scope slides (Dako, Glostrup, Denmark). Paraffin sections were heated for 30 min at 60˚C
(Function Line UT12, Heraeus Instruments, Hanau, Germany) and stored at 4˚C until
staining.
Histological staining
Hematoxylin and eosin (H&E) staining and periodic acid Schiff (PAS) staining of paraffin sec-
tions were performed according to standard protocols. Stainings were visualised by light
microscopy (BX51, Olympus, Ballerup, Denmark) and images obtained with digital camera
(UC30, Olympus, Ballerup, Denmark).
Immunostaining
Deparaffinisation of sections and antigen retrieval were performed by pretreatment in PT Link
(Dako, Glostrup, Denmark). Sections were pretreated in EnVision FLEX Target Retrieval
Solution HigH pH (Dako, Glostrup, Denmark), except for staining with fibroblast antibody,
which required pretreatment in EnVision FLEX Target Retrieval Solution Low pH (Dako,
Glostrup, Denmark). Sections were blocked and permeabilised in PBS with 2% fetal calf
serum, 1% bovine serum albumin (BSA) and 0.25% Triton X-100 for 30 min. Primary antibod-
ies diluted in incubation buffer (PBS with 1% BSA and 0.25% Triton X-100) were applied to
sections and incubated for 1 h at RT. The used primary antibodies were monoclonal rabbit-
anti-epithelial cell adhesion molecule (EpCAM) (clone E144, Abcam, Cambridge, United
Kingdom) diluted 1:400, monoclonal mouse-anti-cytokeratin 20 (clone Ks20.8, Dako,
Glostrup, Denmark) diluted 1:100, monoclonal mouse-anti-carcinoembryonic antigen (CEA)
(clone II-7, Dako, Glostrup, Denmark) diluted 1:50, monoclonal mouse-anti-fibroblasts (clone
TE-7, Millipore, Billerica, MA, USA) diluted 1:100, monoclonal mouse-anti-Ki67 (clone MIB-
1, Dako, Glostrup, Denmark) diluted 1:100, monoclonal mouse-anti-ABCB1 (P-glycoprotein)
(clone JSB-1, Abcam, Cambridge, United Kingdom) diluted 1:50 and monoclonal mouse-anti-
ABCG2 (breast cancer resistance protein) (clone BXP-21, Abcam, Cambridge, United King-
dom) diluted 1:100. Secondary antibodies diluted in incubation buffer were applied to sections
and incubated for 30 min at RT. The used secondary antibodies were goat-anti-rabbit Alexa
546 and goat-anti-mouse Alexa 488, both diluted 1:400. Sections were stained with 3 μM
Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 5 min and coverslips were
mounted with fluorescence mounting medium (Dako, Glostrup, Denmark). Negative control
sections were obtained by omission of primary antibody. Stainings were visualised by fluores-
cence microscopy (Axio Lab.A1, Zeiss, Birkerød, Denmark) and images obtained with digital
Spheroid culture as an in vitro model for personalizing cancer medicine
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camera (DMK 72AUC02, The Imaging Source, Bremen, Germany). The number of stained
cells was analysed on the obtained images using Image J. The percentage of stained cells was
compared by paired-samples t test, Wilcoxon signed-rank test or by one-way repeated-mea-
sures ANOVA.
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
staining
Deparaffinisation of sections and antigen retrieval was performed by pretreatment in PT Link
in EnVision FLEX Target Retrieval Solution HigH pH. TUNEL staining was performed using
the ApopTag Fluorescein In Situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA)
according to the manufacturer’s instructions for fluorescent staining of paraffin-embedded tis-
sue. Positive control sections were obtained by pretreatment with 1 μg/ml DNase I (Sigma-
Aldrich, St. Louis, MO, USA) in PBS with 4 mM MgCl2 for 10 min at RT. Negative control sec-
tions were obtained by omission of TdT enzyme. Co-staining with EpCAM was performed as
described in the previous section. Stainings were visualised by fluorescence microscopy and
images obtained. The number of stained cells was analysed on the obtained images using
Image J. The percentage of stained cells was compared by paired-samples t test.
Chemosensitivity testing
After 3 days of culture, spheroids were washed in PBS, filtered, resuspended in fresh stem cell
medium and counted. For each screen, approximately 1000 spheroids were added to an Indi-
Treat™ screening array (2cureX, Birkerød, Denmark) containing concentration gradients of
5-FU, oxaliplatin, SN38 (the active metabolite of Irinotecan) (Sigma-Aldrich, St. Louis, MO,
USA) and combination treatments FOLFOX (5-FU + oxaliplatin) and FOLFIRI (5-FU and
SN38). The arrays were scanned on screening day 0, 4 and 7 using an oCelloScope system
(Phillips BioCell, Allerød, Denmark). The obtained images were analysed for changes in spher-
oid area using proprietary Phillips BioCell and 2cureX algorithms. For each well, the relative
growth inhibition was calculated by dividing the total spheroid area with the area of the same
well at day 0 and the average of the negative controls on the same day as the measurement day.
Dose response curves, adjusted r2 values and ED25 values were plotted and calculated using
Matlab (MathWorks, Natik, MA, USA). Less than lowest dose or higher than highest dose was
used in cases where ED25 values were calculated to be outside the used compound concentra-
tion ranges.
Statistical analysis
All statistical analyses were performed in IBM SPSS statistics 20 (Armonk, New York, USA). A
p-value 0.05 was considered statistically significant.
Results
Spheroid cultures can be established from colorectal adenocarcinomas
with a high success rate
For 20 tumour samples, the efficiency of culture establishment was evaluated. Two neuroendo-
crine carcinomas were excluded from the study after receiving the histopathological reports.
For tumours diagnosed as adenocarcinomas (n = 18), spheroid cultures were successfully
established for 15 (83%) of the obtained samples. One of these tumours was classified as a
mucinous adenocarcinoma. The clinical characteristics of the tumours are listed in S1 Table.
Spheroid culture as an in vitro model for personalizing cancer medicine
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Colorectal spheroids consist of epithelial cells with little fibroblast
contamination
Three different sizes of spheroids were prepared for each tumour in order to investigate if the
size of the isolated tumour fragments affects spheroid formation and cellular characteristics of
spheroids (Fig 1A). Despite individual variation in spheroid forming efficacy between tumours,
varying from 40% to more than 90% (Fig 1B), no significant difference in spheroid forming effi-
cacy was found for the three fragment sizes (mean with 95% CI: 100–230 μm = 56.8% (36.6–
76.9), 40–100 μm = 62.5% (42.6–82.4), 30–40 μm = 60.5% (40.3–80.6); p = 0.054).
The cell composition of spheroids was assessed by immunostaining for the epithelial
marker EpCAM and the fibroblast marker TE-7 after establishment of cultures (day 3) and
after short-term culture (day 10). Staining revealed that the spheroids consisted of an almost
pure population of epithelial cells with very little fibroblast contamination (Fig 1C). The per-
centage of spheroid cells stained for EpCAM ranged from 96.7% to 100%, whereas the percent-
age stained for TE-7 ranged from 0% to 4.3% (Fig 1D). The proportion of EpCAM- and TE-
7-positive cells did not change significantly from day 3 to day 10 in culture.
Fig 1. Colorectal spheroid cultures predominantly consist of epithelial cells. (A) Spheroids of three different sizes at low and high
magnification after 3 days of culture. Size bar = 50 μm. (B) Spheroid forming efficacy of isolated tumour fragments. Spheroid forming efficacy was
defined as the percentage of isolated tumour fragments that had formed spheroids within 3 days of culture. (C) Immunostaining of spheroids for
epithelial cell marker EpCAM (red) and fibroblast marker TE-7 (green) after 10 days of culture. Nuclei are stained with Hoechst (blue). Size
bars = 50 μm. (D) No significant difference in percentage of spheroid cells stained for EpCAM (p = 0.387) and TE-7 (p = 0.196) at day 3 and day 10
was observed.
https://doi.org/10.1371/journal.pone.0183074.g001
Spheroid culture as an in vitro model for personalizing cancer medicine
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Colorectal spheroids grow and maintain viability in short-term culture
Growth of individual spheroids was monitored over 7 days. All spheroid cultures demon-
strated a significant increase in relative size over a period of 7 days (p = 0.001) (Fig 2A). Spher-
oid growth for different cultures ranged from 1.4-fold to 3.4-fold increase in size and growth
for all cultures averaged 2.6-fold increase in size. No significant difference in average growth
was observed for the three different spheroid sizes (Fig 2B).
Spheroid sections were assessed for active proliferation by immunostaining for the prolifer-
ation marker Ki67 and apoptosis by TUNEL staining (Fig 2C). The percentage of EpCAM-
positive cells expressing Ki67 at day 3 varied from 9% to 63% for different spheroid cultures
(Fig 2D). Overall, no significant change in the percentage of Ki67-positive cells could be
detected from day 3 to day 10 in culture. Very few apoptotic cells could be detected in the
established spheroid cultures. On average, less than 5% of the EpCAM-positive cells stained
Fig 2. Spheroid growth and viability in short-term culture. (A) Significant growth of spheroid cultures from different tumours during 7 days of
culture (p = 0.001). Growth of individual spheroids after 7 days was measured as the spheroid area on microscopic images with the area at baseline
set to 1. Bars display mean values with standard error of the mean (SEM) for all three sizes of spheroids. (B) No significant difference in growth of
different sizes of spheroids during 7 days of culture (p = 0.617). Growth of individual spheroids was measured as the spheroid area on microscopic
images obtained every day with the area at baseline set to 1. Curves display mean values with SEM for one representative patient. Size bar = 50 μm.
(C) Immunostaining of spheroids for epithelial cell marker EpCAM (red), active proliferation marker Ki67 (green) and apoptotic assay TUNEL (green)
after 10 days of culture. Nuclei are stained with Hoechst (blue). Size bars = 50 μm. (D) No significant difference in percentage of EpCAM-positive
spheroid cells stained for Ki67 (p = 1.000) and TUNEL (p = 0.454) at day 3 and day 10 was observed. Ki67: Median with interquartile range. TUNEL:
Mean with 95% CI.
https://doi.org/10.1371/journal.pone.0183074.g002
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with TUNEL (Fig 2D). The percentage of apoptotic cells did not change significantly from day
3 to day 10 in culture.
Spheroid culture preserves colorectal adenocarcinoma histology
H&E staining confirmed that spheroids consisted of cells displaying classical neoplastic fea-
tures, such as nuclear pleomorphism, increased nucleus/cytoplasm ratio, hyperchromasia and
prominent nucleoli (Fig 3A and 3B). Spheroid cells were organised in glandular-like structures
Fig 3. Spheroid cultures preserve cytology and histology of their original tumours. (A-C) H&E and
PAS staining of spheroids and corresponding tumours from three different patients. Spheroids were stained
after 10 days of culture. Size bars = 50 μm.
https://doi.org/10.1371/journal.pone.0183074.g003
Spheroid culture as an in vitro model for personalizing cancer medicine
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with polarized, aligned nuclei and luminal areas, and the degree of glandular organisation in
spheroids generally reflected the original tumour. PAS staining demonstrated that pink
mucin-producing cells were present to varying degree in spheroids from different tumours
(Fig 3A and 3B). In some spheroids, mucin secretion into luminal areas could be observed (Fig
3B).
Primary colorectal spheroids preserve protein expression patterns of the
original tumour
Cytokeratin 20 is a cytoskeletal protein that is expressed by intestinal epithelial cells, especially
those of the colon [34]. Immunostaining revealed that cytokeratin 20 was expressed to a vary-
ing degree by spheroid cultures established from different tumours (Fig 4A). For some cul-
tures, variation in cytokeratin 20 expression for individual spheroids obtained from the same
tumour could be observed. This variation reflected expression in different regions of the origi-
nal tumour (S1 Fig). Overall, the average percentage of positive cells in the original tumour
and the derived spheroids was comparable (Fig 4B). The percentage of EpCAM-positive cells
expressing cytokeratin 20 was not significantly different between sections from the original
tumour, spheroids at day 3 and spheroids at day 10. A few of the established cultures deviated
from the original tumour; spheroids from patient 4 had a much higher expression of cytokera-
tin 20, while spheroids from patient 15 showed somewhat lower cytokeratin 20 expression at
day 10.
CEA is a glycoprotein that is often overexpressed in epithelial cancers, including colorectal
carcinoma [35]. The spheroid cultures exhibited variations in their CEA expression patterns
and levels (Fig 5A). Some cultures showed variation in CEA expression for individual spher-
oids which resembled expression patterns in different regions of the original tumours (S2 Fig).
For most patients, expression in tumour tissue and spheroid cultures was comparable (Fig 5B).
However, for several spheroid cultures expression at day 3 was higher than both the expression
in the original tumour and at day 10. Overall, a significant difference in the percentage of
EpCAM-positive cells expressing CEA in tumour sections, spheroids at day 3 and spheroids at
day 10 was detected (p = 0.040), but Bonferroni corrected post hoc analysis did not reveal any
significant differences when performing pairwise comparisons. The obtained results indicated
that the percentage of cells expressing CEA was higher at day 3 compared to the tumour and
day 10, but the differences did not reach significance.
Individual spheroid cultures exhibit variation in chemosensitivity
The chemosensitivity of spheroids from five tumour samples were tested using IndiTreat™
arrays. Dose dependent inhibition of spheroid growth was observed for all the investigated
drugs (5-FU, oxaliplatin and SN38) and combination treatments (FOLFOX and FOLFIRI).
The resulting dose response curves and calculated ED25 values showed clear differences in
sensitivity towards the different chemotherapeutic drugs. ED25 values for all of the screened
cultures are shown in the table in Fig 6A. Dose response curves for two representative cultures
are shown in Fig 6B. One of the examined cultures displayed differential sensitivity to the che-
motherapeutic drugs (patient 22). Two of the spheroid cultures demonstrated high sensitivity
to all the tested drugs (patient 19 and 21), whereas the two remaining cultures were generally
more resistant (patient 20 and 23).
Several of the spheroid cultures displayed either general sensitivity or resistance to all the
tested drugs. This could be caused by multidrug resistance mechanisms, such as drug efflux by
ATP-dependent pumps [36]. The ATP-binding cassette transporters ABCG2 and ABCB1 have
previously been associated with chemotherapy resistance, early disease recurrence and shorter
Spheroid culture as an in vitro model for personalizing cancer medicine
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Fig 4. Spheroid cultures preserve cytokeratin 20 expression of their original tumours. (A) Immunostaining
of spheroids and corresponding tumours from two different patients for epithelial cell marker EpCAM (red) and
gastrointestinal epithelial marker cytokeratin 20 (green). Nuclei are stained with Hoechst (blue). Spheroids were
stained after 10 days of culture. Size bars = 50 μm. (B) No significant difference in percentage of EpCAM-positive
cells stained for cytokeratin 20 in tumours and spheroid cultures at day 3 and day 10 (p = 0.149) was observed.
https://doi.org/10.1371/journal.pone.0183074.g004
Spheroid culture as an in vitro model for personalizing cancer medicine
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Fig 5. Spheroid cultures preserve CEA expression of their original tumours. (A) Immunostaining of
spheroids and corresponding tumours from two different patients for epithelial cell marker EpCAM (red) and
adenocarcinoma marker CEA (green). Nuclei are stained with Hoechst (blue). Spheroids were stained after
10 days of culture. Size bars = 50 μm. (B) Significant difference in percentage of EpCAM-positive cells stained
for CEA in tumours and spheroid cultures at day 3 and day 10 (p = 0.040), but Bonferroni corrected post hoc
analysis did not reach statistical significance (tumour vs. day 3 p = 0.139, tumour vs. day 10 p = 1.000 and day
3 vs. day 10 p = 0.158).
https://doi.org/10.1371/journal.pone.0183074.g005
Spheroid culture as an in vitro model for personalizing cancer medicine
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survival in colorectal cancer [37–39]. Immunostaining of the original tumours demonstrated
that the cancer cells expressed ABCG2 in all five tumours, but to varying extent (Panel A in S3
Fig). Four out of five examined colorectal tumours expressed ABCB1, however only few posi-
tive cancer cells were detected (Panel B in S3 Fig). Neither ABCG2 nor ABCB1 expression
seemed to reflect overall chemosensitivity of the derived spheroid cultures.
Discussion
Development of functional assays for predicting chemosensitivity of individual tumours is
needed to improve clinical response rates. 3D culture of cancer cells is considered to reflect the
in vivo tumour conditions more closely than conventional 2D culture and therefore represents
a promising system for chemosensitivity testing. In the current study, colorectal cancer cells
were isolated as tumour fragments and cultured in 3D as spheroids. Characterisation of the
spheroids showed that important properties of the original tumour were retained during
short-term (i.e. up to 10 days) in vitro culture. Importantly, spheroid cultures displayed hetero-
geneous response profiles when exposed to chemotherapy.
Spheroid cultures were successfully established in 83% of the colorectal adenocarcinoma
samples. Staining confirmed that the spheroids consisted of epithelial-derived neoplastic cells.
Two previous studies have reported a high overall success rate in establishing spheroid suspen-
sion cultures (99% and 89%) from resected colorectal tissue [31,33], while a third study only
reported a success rate approximating 50% [30]. Differences in definition of “a successful cul-
ture” might explain some of the variation in success rates. Furthermore, the media composi-
tion might affect the success rate. Like the two studies reporting high success rates, we
established cultures in serum-free medium, whereas the study with low culture success used
serum-containing medium. This indicates that serum-free medium is more efficient for form-
ing colorectal spheroids. In the study by Ashley et al., addition of ROCK1 inhibitor to the cul-
ture medium increased the success rate dramatically both in terms of establishing (from 75%
to 100%) and maintaining cultures short-term (from 46% to 89%) [33]. ROCK1 inhibitor has
been shown to reduce dissociation-induced apoptosis, known as anoikis, in both embryonic
stem cell cultures and primary intestinal cultures [40,41]. Even though we did not add any
inhibitors to the culture media, our success rate was comparable to the achieved short-term
culture success in the study using ROCK1 inhibitor.
As in previous spheroid studies, we observed that established cultures predominantly con-
sisted of epithelial-derived cells [30,31,33,42]. This is important, because overgrowth by fibro-
blasts remains one of the major challenges when culturing primary colorectal cancer cells in
conventional 2D culture [43,44]. Immunostaining for the fibroblast marker TE-7 showed that
only few fibroblasts were found in the spheroid cultures and no increase in fibroblasts was
observed during culture. Studies have shown that fibroblasts grow poorly under serum-free
culture conditions [45–47] which could explain the low number of fibroblasts detected in our
spheroids. As more than 95% of cells in the spheroids stained for EpCAM and the percentage
of EpCAM positive cells did not decrease with time in culture, staining for other stromal cells
was not performed. In line with our observations, previous studies only detected few fibro-
blasts, endothelial and immune cells in primary colorectal spheroids [31,33,42], but the cell
composition of spheroids over time was not studied.
Fig 6. Chemosensitivity screening is possible using spheroid cultures. (A) Screening results for spheroid cultures
exposed to common chemotherapy drugs and combinations from five patients. ED25: the dose at which a given drug
resulted in 25% growth reduction compared to untreated spheroids. * poor curve fit, however, max growth reduction was
17% so ED25 was assigned >500nM. (B) Curve fit graphs for Pt.20 and Pt.21 demonstrating different chemosensitivity
profiles.
https://doi.org/10.1371/journal.pone.0183074.g006
Spheroid culture as an in vitro model for personalizing cancer medicine
PLOS ONE | https://doi.org/10.1371/journal.pone.0183074 September 6, 2017 13 / 19
A significant increase in spheroid size could be observed over a 7 day period for all the stud-
ied cultures. Interestingly, spheroid growth rate did not depend on size of the isolated tumour
fragments, at least not within the investigated range. These results indicate that all the investi-
gated spheroid sizes can be used for assaying growth and growth inhibition as a measure of
drug sensitivity. Variation in growth rate was evident for cultures from different tumours,
indicating that some intertumour heterogeneity was preserved. During 10 days of culture,
active proliferation persisted in spheroids and very limited apoptosis was detected. Taken
together, these data show that the primary spheroids remain viable for at least 10 days in the
tested culture system.
In line with previous studies [31,33,42,48,49], we have demonstrated that primary colorectal
3D cultures display a number of features found in the original tumours. Histological staining
of established cultures confirmed that spheroids retained characteristic features of colorectal
adenocarcinomas. Furthermore, the degree of glandular organisation was similar to the origi-
nal tumours.
A previous study also identified crypt-like structures in their primary colorectal spheroids
[31]. Like in the present study, epithelial organisation was preserved by isolating cancer cells as
fragments of tumour tissue that maintained cell-to-cell contacts. Many tumours display inher-
ent molecular heterogeneity, and therefore random dissociation of tumour tissue might gener-
ate a heterogeneous population of spheroids. In our study, cultures derived from tumours with
varying expression of cytokeratin 20 or CEA, also demonstrated variation in expression for
individual spheroids. However, average expression in spheroid cultures was comparable with
the average expression in the original tumours. Spheroid expression seemed to reflect the orig-
inal tumour better after 10 days of culture than after 3 days. This is somewhat surprising, since
it is well-established that cancer cells maintained in culture for longer time tend to become
more deviating from their original tumour [50–52]. However, in this context 10 days is a rela-
tively short time and molecular evolution might not have occurred yet. On day 3 the cultured
cells might still be stressed from the isolation procedure performed on day 0. Tissue hypoxia,
dissociation of tissue and artificial culture conditions can induce cellular stress responses that
generate changes in e.g. protein expression and cell signalling [53–55]. Therefore, it might be
important to consider the time since isolation when conducting experiments with spheroids.
We have demonstrated that chemosensitivity testing is possible using the IndiTreat™ screen-
ing array combined with tumour spheroids derived from both primary colorectal tumours and
metastases. The results from five screens show varying sensitivities towards the chemotherapeu-
tic drugs most commonly used for treatment of colorectal cancer. To our knowledge, this is the
first time all the drugs used for first-line treatment of colorectal cancer (both as mono and com-
bination therapies) have been tested on patient-derived tumour spheroids. Our results are in
line with previous studies that also have observed variation in the sensitivity of 3D cultures
derived from different colorectal tumours [31,42,48]. This coincides well with the heterogeneity
of response seen when patients are treated with chemotherapy, indicating that chemosensitivity
testing on tumour-derived spheroids may be useful in treatment selection. Importantly, the
short time from sample to result (10–14 days) presented in the current study means that treat-
ment selection can be accomplished in a patient-relevant timeframe. Van de Wetering et al.
[48] observed organoid cultures displaying general sensitivity or resistance to chemotherapy. In
agreement with their results, two of the spheroid cultures examined in the present study exhib-
ited generally higher sensitivity to all the tested drugs. Two drug resistance mechanisms relevant
to 3D culture are lack of drug penetration [56] or active drug efflux by e.g. ATP-dependent
pumps [36]. The spheroids used for chemosensitivity screening were all of similar size. Conse-
quently, the observed differences in drug sensitivity are not likely to be caused by size-mediated
variance in drug penetration. Likewise, ABCG2 and ABCB1 expression levels in the original
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tumours did not explain the multidrug resistance observed in the derived cultures. This sup-
ports that functional in vitro characterisation of cancer cell chemosensitivity provides additional
information to biomarker profiling of the tumour tissue.
In conclusion, primary colorectal spheroids generated in the present study successfully
maintained histology and protein expression patterns of their original tumours. Our screening
results indicate that patient-to-patient differences in response to chemotherapy are present in
the spheroid cultures. Short-term spheroid culture of patient-derived cancer cells therefore
represents a promising in vitro model for use in individualized medicine. Further studies are
needed to determine how spheroid cultures functionally relate to the original tumour, espe-
cially in terms of chemosensitivity. To facilitate this, we are currently performing an interven-
tional study to validate the screening system. In addition, more detailed investigation of
intratumour heterogeneity and how this translates to the established spheroid cultures would
be of clinical interest.
Supporting information
S1 Table. Overview of included patients. All tumours were classified as adenocarcinomas,
except for one mucinous adenocarcinoma denoted with a . MSI: microsatelite instability, MSI
was not determined for liver metastasis (pt: 21, 22 & 23), M: male, F: female.
(DOC)
S1 Fig. Spheroid cultures and their original tumours display heterogeneity in cytokeratin
20 expression. (A) Immunostaining of spheroids and different tumour areas from the same
patient for epithelial cell marker EpCAM (red) and gastrointestinal epithelial marker cytokera-
tin 20 (green). Nuclei are stained with Hoechst (blue). Spheroids were stained after 10 days of
culture. Size bars = 50 μm.
(TIF)
S2 Fig. Spheroid cultures and their original tumours display heterogeneity in CEA expres-
sion. (A) Immunostaining of spheroids and different tumour areas from the same patient for
epithelial cell marker EpCAM (red) and adenocarcinoma marker CEA (green). Nuclei are
stained with Hoechst (blue). Spheroids were stained after 10 days of culture. Size bars = 50 μm.
(TIF)
S3 Fig. Heterogeneous expression of ABCG2 and ABCB1 in colorectal tumours. (A) Immu-
nostaining for epithelial cell marker EpCAM (red) and ATP-binding cassette transporter
ABCG2 (green). Nuclei are stained with Hoechst (blue). (B) Immunostaining for epithelial cell
marker EpCAM (red) and ATP-binding cassette transporter ABCB1 (green). Nuclei are
stained with Hoechst (blue). Size bars = 50 μm.
(TIF)
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